Interview with the Broad Institute's David Liu: Is this the year base editing makes its mark?

Zachary Brennan

Senior Editor

For those tracking the progress of genome editing, the Broad Institute of Harvard and MIT’s David Liu likely needs no introduction (Google him for a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Interview with the Broad Institute's David Liu: Is this the year base editing makes its mark?

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

Are programs with compounded GLP-1s safe for your population?

In­ter­view with the Broad In­sti­tute's David Liu: Is this the year base edit­ing makes its mark?

Zachary Brennan

Senior Editor

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Interview with the Broad Institute's David Liu: Is this the year base editing makes its mark?

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

Are programs with compounded GLP-1s safe for your population?